Persistent DME more likely with bevacizumab treatment

Persistent DME more likely with bevacizumab treatment

(HealthDay)—For patients with diabetic macular edema (DME), persistence is more likely with bevacizumab than with aflibercept or ranibizumab, according to a study published online Feb. 1 in JAMA Ophthalmology.

Neil M. Bressler, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted post hoc analyses of a clinical trial. Among 546 patients, they examined outcomes of DME persisting at least 24 weeks after randomization to treatment with aflibercept, , or ranibizumab.

The researchers found that through 24 weeks, persistent DME was more frequent with bevacizumab than aflibercept or ranibizumab (65.6 versus 31.6 and 41.5 percent, respectively; P < 0.001 for aflibercept or ranibizumab versus bevacizumab; P = 0.05 for aflibercept versus ranibizumab). Among eyes with persistent DME through 24 weeks, the rates of chronic persistent DME through two years were 44.2, 68.2, and 54.5 percent with aflibercept, bevacizumab, and ranibizumab, respectively (P = 0.03 for aflibercept versus bevacizumab; P = 0.41 for aflibercept versus ranibizumab; and P = 0.16 for bevacizumab versus ranibizumab). The proportion with versus without chronic persistent DME through two years gaining at least 10 letters from baseline were 62 versus 63 percent with aflibercept (P = 0.88); 51 versus 54 percent with bevacizumab (P = 0.96); and 44 versus 65 percent with (P = 0.1) among eyes with persistent DME though 24 weeks.

"Regardless of persistence or anti-vascular endothelial growth factor agent, few eyes lost substantial vision," the authors write.

Several authors disclosed financial ties to the .


Explore further

High-priced drugs used to treat diabetic macular edema not cost-effective

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: JAMA Ophthalmology

Copyright © 2018 HealthDay. All rights reserved.

Citation: Persistent DME more likely with bevacizumab treatment (2018, February 4) retrieved 25 August 2019 from https://medicalxpress.com/news/2018-02-persistent-dme-bevacizumab-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
4 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more